By Mill Chart
Last update: Feb 14, 2024
Our stock screener has spotted SANOFI-ADR (NASDAQ:SNY) as a good dividend stock with solid fundamentals. NASDAQ:SNY shows decent health and profitability. At the same time it gives a good and sustainable dividend. We'll dive into each aspect below.
To gauge a stock's dividend quality, ChartMill utilizes a Dividend Rating ranging from 0 to 10. This comprehensive assessment considers various dividend aspects, including yield, history, growth, and sustainability. NASDAQ:SNY has achieved a 8 out of 10:
ChartMill employs a unique Health Rating system for all stocks. This rating, ranging from 0 to 10, is determined by analyzing various liquidity and solvency ratios. For NASDAQ:SNY, the assigned 5 for health provides valuable insights:
ChartMill employs its own Profitability Rating system for stock evaluation. This score, ranging from 0 to 10, is derived from an analysis of diverse profitability metrics and margins. In the case of NASDAQ:SNY, the assigned 7 is noteworthy for profitability:
More Best Dividend stocks can be found in our Best Dividend screener.
Our latest full fundamental report of SNY contains the most current fundamental analsysis.
Important Note: The content of this article is not intended as trading advice. It is essential to perform your own analysis and exercise caution when making trading decisions. The article presents observations created by automated analysis but does not guarantee any trading or investment outcomes. Always trade responsibly and make independent judgments.
SANOFI-ADR
NASDAQ:SNY (4/19/2024, 7:16:58 PM)
After market: 46.3 0 (0%)46.3
+0.91 (+2%)
Vertex hopes Alpine's drug can be tested on other conditions beyond the one entering Phase 3 trial for a kidney disease.
Auddia stock is taking off on Monday with heavy trading of AUUD stock after the company received a new AI tech patent.
Apartment Income REIT stock is rising higher on Monday as investors in AIRC shares react to a deal to take the company private.
Sanofi layoffs are coming for the company's R&D employees and it makes major changes to how it handles development going forward.
With the Fear and Greed Index at 69, it's an opportune to wager on these attractive Stocks with Moonshot Potential.
With certain sectors in the domestic market appearing overstretched, these global growth stocks may offer better opportunities.
Given recent industry performance, the enthusiasm investors have for biotech stocks to buy is low. But these three companies seem promising.